• Home

  • About Us

  • Categories

  • Events

  • Sharing

  • News & Updates

  • Blogs and Articles

  • Slack

  • Feed Back

  • Organiser

  • More

    EN
    EN
    ES
    PT
    RU

    1/3

    COVID Rx Exchange

    A Global Nonprofit Initiative 

             Between Doctors

    Pharmacotherapy

    Therapeutic Management
    Therapeutic Management
    IDSA Guidelines
    IDSA Guidelines
    Potential interventions for novel coronavirus
    Potential interventions for novel coronavirus
    Current status of potential therapies
    Current status of potential therapies
    Individual risk management strategy
    Individual risk management strategy
    COVID19 Vaccines
    COVID19 Vaccines
    Covid: current status and future perspectives
    Covid: current status and future perspectives
    Coronavirus Disease 2019 Treatment
    Coronavirus Disease 2019 Treatment
    R&D on Therapeutic Agents and Vaccines
    R&D on Therapeutic Agents and Vaccines
    Inactivated vaccine candidate
    Inactivated vaccine candidate
    Molecular Basis of Vaccine Development
    Molecular Basis of Vaccine Development
    Vaccine Worksheet Factsheet
    Vaccine Worksheet Factsheet
    Adjunct immunotherapies Severely Ill patients
    Adjunct immunotherapies Severely Ill patients
    COVID measles immunisation IAP
    COVID measles immunisation IAP
    Hydroxychloroquine prophylaxis for India
    Hydroxychloroquine prophylaxis for India
    Drug discovery and therapeutic options
    Drug discovery and therapeutic options
    Broad-spectrum coronavirus antiviral drug discovery
    Broad-spectrum coronavirus antiviral drug discovery
    COVID Pharmacotherapy Review
    COVID Pharmacotherapy Review
    Advisory on the use of Hydroxychloroquin
    Advisory on the use of Hydroxychloroquin
    Recovery-collaborators-meeting
    Recovery-collaborators-meeting
    Off-Label Treatments for COVID-19
    Off-Label Treatments for COVID-19
    Triple combination Open Label Randomized
    Triple combination Open Label Randomized
    Pharmacologic Treatments for Coronavirus
    Pharmacologic Treatments for Coronavirus
    Convalescent Plasma Review.pdf
    Convalescent Plasma Review.pdf
    Remdesivir in COVID-19
    Remdesivir in COVID-19
    Hydroxychloroquine usage in United States
    Hydroxychloroquine usage in United States
    Convalescent Plasma.pdf
    Convalescent Plasma.pdf
    Convalescent sera option.pdf
    Convalescent sera option.pdf
    Convalescent Plasma For Clinicians.pdf
    Convalescent Plasma For Clinicians.pdf
    COVID Plasma Mayo 05272020.pdf
    COVID Plasma Mayo 05272020.pdf
    Convalescent Plasma Severe.pdf
    Convalescent Plasma Severe.pdf
    COVID Plasma Mayo Clinic 05042020.pdf
    COVID Plasma Mayo Clinic 05042020.pdf
    CP Early Indicators Mar 2020.pdf
    CP Early Indicators Mar 2020.pdf
    CP Effectiveness of CBP China.pdf
    CP Effectiveness of CBP China.pdf
    Epidemiology, Dx and Rx of Covid
    Epidemiology, Dx and Rx of Covid
    Convalescent Plasma Challanges.pdf
    Convalescent Plasma Challanges.pdf
    CP and ADE Mar 2020.pdf
    CP and ADE Mar 2020.pdf
    CP Resurgence - Editorial.pdf
    CP Resurgence - Editorial.pdf
    FAQ - CP Treatment Preestablish Protocol.pdf
    FAQ - CP Treatment Preestablish Protocol.pdf
    Fenofibrate targets host metabolisim
    Fenofibrate targets host metabolisim
    CP to Treat COVID-19.pdf
    CP to Treat COVID-19.pdf
    CP Donor Motivation May 2020.pdf
    CP Donor Motivation May 2020.pdf
    CP Trial Prot 05182020.pdf
    CP Trial Prot 05182020.pdf
    Substances-human-origin ECDC03202020.pdf
    Substances-human-origin ECDC03202020.pdf
    Math+ Plus Protocol
    Math+ Plus Protocol